• EN

Bulgaria country overview — a summary of the national drug situation



Bulgaria country overview
A summary of the national drug situation

Map of Bulgaria

Our partner in Bulgaria

The national focal point on Drugs and drug addiction (NFP) is based in the National Centre for Addictions. The unit carries out informational, analytical, scientific research, expert-consultative and publishing activities. The main objectives of NFP activities include methodological control, collection, evaluation and classification... Read more »

National Centre for Addictions

117, Pirotska Str.
BG-1303 Sofia
Tel. +359 28313079
Fax +359 28321047

Head of focal point: Mr Momtchil Vassilev

Our partner in Bulgaria

National Centre for Addictions

117, Pirotska Str.
BG-1303 Sofia
Tel. +359 28313079
Fax +359 28321047

Head of focal point: Mr Momtchil Vassilev

The national focal point on Drugs and drug addiction (NFP) is based in the National Centre for Addictions. The unit carries out informational, analytical, scientific research, expert-consultative and publishing activities. The main objectives of NFP activities include methodological control, collection, evaluation and classification, processing, storage, analysis and dissemination of information in the field of drug demand and supply in Bulgaria, drugs policy and the response to the situation in that field. The NFP works on the provision of information, supporting the activity of the National Drug Council and the formulation of a state policy towards drugs and drug addiction.

E-mail addresses have been inserted in a way discouraging spam. Please replace [a] by @ before actually using any of the e-mail addresses.

Drug use among the general population and young people

A fourth national representative study among the general population was carried out in Bulgaria in 2012 with a sample of 5 325 people aged 15–64 on their use of and attitudes towards different psychoactive substances (the previous surveys were in 2005, 2007 and 2008). The data indicated that cannabis was the most frequently used substance, with last year prevalence at 3.5 % and last month prevalence at 2.0 %. When compared to the previous studies, a steady and significant increase in last year and last month prevalence of cannabis use was reported among the general population. Cannabis also remained the most frequently used illicit substance among young adults aged 15–34. Last year and last month prevalence also increased among this age group when compared to previous years: in 2012 a total of 8.3 % reported they had used cannabis at least once in the last 12 months, while the rate was 6.0 % in 2008, and 4.4 % in 2007. For the same age group, last month prevalence of cannabis use was 4.8 % in 2012, an increase from 1.4 % in 2008 and 1.2 % in 2007. Ecstasy was the second most prevalent substance, and the studies show an increase in its use since 2007, in particular among younger adults. Prevalence of amphetamines, cocaine and heroin use has remained low among the general population, and the latest study confirmed a declining trend in the reported use of these substances since 2005.

In 2011, the European School Survey Project on Alcohol and Other Drugs (ESPAD) was conducted among 15- to 16-year-old students for the fourth time, with a sample size of 2 217. The reported lifetime prevalence of cannabis use was 24 %, compared to 22 % in 2007 and 21 % in 2003. Last year prevalence of cannabis use was 18 %, and last month prevalence was 10 %, which is slightly higher than was reported in 2007 (17 % and 7 % respectively). Lifetime prevalence of amphetamines use was 7 % in 2011, while for inhalants, ecstasy and cocaine it was 4 %. In 2007 lifetime prevalence rates were higher among males than females for all substances. The 2011 study found that males reported ever having used cannabis, ecstasy or LSD more frequently than females, whilst the rates for heroin and cocaine use were similar for males and females; however, lifetime prevalence of amphetamines and inhalant use was higher among females. It should be noted that the lifetime prevalence of cannabis use decreased from 27 % in 2007 to 25 % in 2011 among males, while it increased from 18 % to 22 % among females over the same period. Last year and last month prevalence rates for cannabis use were similar for both genders in the 2011 study. In 2013 the national focal point implemented a national representative survey with a sample of 3 001 high school students in classes 9 to 12. The results largely corroborate the findings of the ESPAD study, indicating that cannabis is the most popular illicit substance used by the students, followed by stimulants (amphetamine, cocaine and ecstasy).

A study of drug use among a representative sample of students from 29 different universities across the country was conducted in 2010, and national surveys on the attitudes towards and use of psychoactive substances among children living in institutions was carried out in seven establishments.

Look for Prevalence of drug use in the 'Statistical bulletin' for more information  

High-risk drug use

Up to 2012 the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) defined problem drug use as injecting drug use (IDU) or long duration/regular use of opiates, cocaine and/or amphetamines. However, in 2012 a new definition of ‘high-risk drug use’ was adopted. The new definition includes ‘problem drug use’, but is broader (mainly in its inclusion of high-risk use of more substances). Details are available here.

Based on data from the 2012 general population study, it is estimated, that about 0.2 % of 15- to 64-year-olds in Bulgaria had used cannabis daily or almost daily within the past 30 days. No other estimates for an individual substance are available.

The available national estimate of problem drug use dates back to 2009 using the capture–recapture method with data sets from the police, emergency medical care and specialised addiction treatment facilities. The estimate indicated that there were 31 316 problem drug users in Bulgaria (range: 23 050–42 920), which is about 6.0 per 1 000 people aged 15–64 (95 % CI: 4.4–8.2).

Look for High risk drug-use in the Statistical bulletin for more information.  

Treatment demand

Treatment demand data are collected through the National Monitoring System for Drug-Related Treatment Demand. Treatment demand data for 2013 were based on data from 32 outpatient units, 22 inpatient treatment units, and 12 treatment units in prisons. A total of 2 193 clients entered treatment, of which 489 were new clients entering treatment for the first time.

Similar to previous years, in 2013 opioids, mainly heroin and mostly used by injection, were the most-reported primary drugs by all treatment clients, at 93 %. Among new treatment clients, 211 stated opioids as the main drug of use, which is about 79 % of those clients for whom a primary substance was reported.

In 2013, the mean age of all and new treatment clients was similar – 30 and 29 years on average. The gender distribution of all treatment clients has remained stable over the last 12 years at 81 % male and 19 % female.

Look for Treatment demand indicator in the Statistical bulletin for more information.  

Drug-related infectious diseases

Until 2004 only sporadic cases of human immunodeficiency virus (HIV) linked to injecting drug use were notified in Bulgaria. Since 2004, however, there has been a steady increase in new HIV cases linked to injecting drug use, from seven cases in 2004 to 74 cases in 2009, with a reduction in the following years. In 2013 the Ministry of Health reported 200 new HIV positive cases, of which 33 were linked to injecting drug use.

Data on the prevalence of drug-related infectious diseases among current injecting drug users are reported by the Laboratory of the Blood Transmitted Infections Department at the National Centre for Addictions (NCA) in Sofia. The data refer to NCA patients and clients of outreach programmes in Sofia. Additional information is gathered from testing clients who enter drug treatment programmes (opioid substitution treatment and rehabilitation) in the regional treatment centres of Blagoevgrad, Bourgas, Pazardjik, Pernik, Pleven, Plovdiv, Sofia and Varna.

In 2013, the prevalence of HIV was 3.4 % of treatment clients who inject drugs in a sample of 812 people tested in Sofia, with higher prevalence rates in the younger age groups (below 25 years). Among 756 treatment clients tested, the prevalence of hepatitis B virus (HBV) infection (positive HBsAg) was 4.5 %. The prevalence of hepatitis C virus (HCV) infections was 62.7 % from a sample of 812 treatment clients, which indicates some reduction when compared to levels in 2010–11. It should be noted that HIV and HCV prevalence is slightly higher among clients tested in eight regional treatment centres, when compared to those tested by NCA.

Look for Drug-related infectious diseases in the Statistical bulletin for more information.  

Drug-induced deaths and mortality among drug users

Data on drug-induced deaths are collected by the General Mortality Registry (GMR) at the National Institute of Statistics. Data extraction and reporting is in line with the EMCDDA definitions for ‘Selection B’, although there is little clarity about the use of T-codes in GMR coding practices. This might lead to an underestimation due to some cases not being extracted and reported as drug-induced deaths.

The overall number of direct drug-induced deaths in Bulgaria is low. There was a significant increase in 2008, when 74 deaths were registered, though this was followed by a decline to 21 in 2013. All but three deaths in 2013 were males. The mean age at the time of death was 32 years. Opioids were involved in nine deaths. The year 2008 remains the high point in the number of drug-induced deaths since the start of the period under observation in 1990.

The drug-induced mortality rate among adults (aged 15–64) was 4.3 deaths per million in 2012, below the European average of 17.1 deaths per million.

Look for Drug-related deaths in the Statistical bulletin for more information.  

Treatment responses

The NCA is the main body entrusted with organising and ensuring the quality of substance abuse treatment, which is done through methodological guidance and training professionals. The NCA compiles a number of registers that document available treatment options, so that coordination of the different treatment programmes can also be improved.

Drug-related treatment is mainly delivered by a combination of public and private institutions and in outpatient and inpatient settings. As a general rule, clients do not pay for treatment received in public institutions, while in private establishments clients pay for the services they receive. Medically assisted treatment, which includes inpatient and outpatient detoxification and opioid substitution treatment (OST), and non-residential and residential psychosocial rehabilitation programmes such as therapeutic communities, day-care centres, etc. are available in Bulgaria. Drug treatment is provided by 12 state psychiatric hospitals, 12 regional mental health centres, 17 psychiatric wards of multi-profiled hospitals offering active treatment and five psychiatric clinics at university hospitals. Non-governmental organisations (NGOs) mainly provide psychosocial services through day-care facilities.

Drug treatment is mainly focused on opioid users, and the most common form of drug-related treatment in Bulgaria remains OST with methadone, which was officially introduced in 1995. Slow-release morphine (Substitol) was also introduced as a recognised substitution drug in 2006. In 2012 several new regulations were adopted that set out the terms and conditions for the provision of treatment with opioid agonists and antagonists. Buprenorphine, registered in the country in 2008, was finally included in the list of substances for substitution treatment. In 2012 there were 30 specialised units delivering OST in 14 cities and towns. A total of 3 563 clients were undergoing OST, 3 419 of whom were on methadone, six were on buprenorphine-based OST, with the remaining on Substitol. Just over a third of clients on methadone maintenance treatment were treated through Ministry of Health or municipally funded programmes. Treatment of the remaining two-thirds of clients, and treatment with Substitol and buprenorphine-based OST, is provided against a monthly co-payment fee paid by clients. Although the evaluation of substitution treatment in 2009 showed that it had contributed toward improvements in the physical and mental well-being of the clients and a reduction in their criminal behaviour, drop-out rates remained one of the main concerns. Methadone maintenance is continued if a client is imprisoned. In 2012 a total of 75 prisoners had received methadone maintenance treatment.

See the Treatment profile for Bulgaria for additional information.  

Harm reduction responses

In Bulgaria, the prevention of overdoses and drug-related infectious diseases is implemented in accordance with the National Strategy to Combat Addictions; the National Programme of Prevention and Control of HIV and Sexually Transmitted Diseases; the Narcotic Substances and Precursors Control Act; the HIV/AIDS Control and Prevention Programme financed by the Global Fund to Fight AIDS, Tuberculosis and Malaria (the project funds will run until 2014); and the Regulation issued by the Minister of Health on terms and conditions for implementing harm reduction programmes, which was adopted in 2011.

In 2012, services to prevent drug-related infectious diseases were provided through needle exchange at 82 fixed sites located in 28 towns, mainly by NGOs. In addition to targeting people who inject drugs, these NGOs also target other risk groups, such as drug users of Roma origin and sex workers, and provide information materials on safe injecting, overdose and infectious diseases, and testing for blood-borne infections in addition to supplying sterile injecting equipment. Services are provided through outreach work in 54 units, four mobile medical consulting rooms and a number of drop-in centres. New demands on the qualification of harm reduction staff are related to the increasing proportion of stimulant injectors among clients at low-threshold facilities. In 2008 an Internet-based system for all agencies providing injecting equipment was set up, improving data reliability and consistency. An estimated 432 000 syringes were distributed through specialised agencies and outreach programmes in 2013. Syringes are also sold at pharmacies, but there are no pharmacy-based programmes providing sterile needles and syringes to PWID.

Ten NGOs, the NCA and 19 medical services in the bigger towns provide anonymous counselling and testing for HIV/acquired immune deficiency syndrome (AIDS). People living with HIV and AIDS are treated in five specialised wards established in clinics for infectious diseases. The government has not implemented specific vaccination campaigns against HBV among drug users since 2000, regardless of the fact that the Action Plan of the National Strategy to Combat Drug Addiction identifies this as one of the subtasks necessary to lower the prevalence of infectious diseases among PWID. It should be noted that in 1993 vaccination against HBV became mandatory in Bulgaria for all newborn infants.

See the Harm reduction overview for Bulgaria for additional information.  

Drug markets and drug-law offences

Bulgaria is mainly considered to be a transit country for all illicit substances, with trafficking activity shaped by supply and demand in western European and Middle Eastern countries. However, some production of synthetic stimulants is consistently reported.

Data on the quantity of drugs seized in Bulgaria is provided by the Chief Directorate for Combating Organised Crime (CDCOC), the Chief Directorate for Counteraction of Criminality, Public Order Preservation and Prevention (National Police Service) at the Ministry of the Interior, and by the National Customs Agency and Border Police.

The Balkan route, used for trafficking heroin from Afghanistan to western Europe, passes through Bulgaria and law enforcement data indicate that heroin is also stored and repackaged in the country. In recent years some criminal groups have also attempted to use the route for cocaine smuggling to central and western Europe. Bulgaria remains a production site of amphetamine and methamphetamine, and has emerged as a producer of some new psychoactive substances. In 2013 a total of 35 clandestine laboratories producing synthetic drugs were detected in the country.

The quantity of all cannabis products seized increased in 2012, but this trend did not continue in 2013, with the exception of cannabis plants. Thus, after a record amount of 15 967 kg of cannabis resin was seized in 2012, only 5.25 kg was reported in 2013. Also, the quantity of herbal cannabis seized in 2013 fell by more than 55 % when compared with 2012 (579.15 kg and 1 319.34 kg respectively). Cannabis plants, which are increasingly cultivated domestically, were the only cannabis product to be seized in greater quantities in 2013, with a new record of 18 126 plants reported. It is assumed that cannabis is cultivated in all regions of Bulgaria; 44 indoor cannabis-growing sites and 25 decares of outdoor cannabis-growing sites were dismantled in 2013.

A total of 156.81 kg of heroin was seized in 2013, confirming the downward trend observed since 2008. In 2013 a total of 158.78 kg and 2 331 tablets of amphetamine and 33.15 kg of methamphetamine were seized, which is an increase compared to 2012. A total of 19.54 kg of cocaine was seized in 2013, which is almost 10 times less than the previous year. With regard to ecstasy, the quantity seized remained below the amounts seized in 2005–06, while an increasing number of seizures containing new psychoactive substances, such as synthetic cannabinoids and cathinones, were observed.

In 2013 Bulgaria recorded 9 521 individuals committing drug-law offences. Some 68.4 % of offences were cannabis-related, and 19.2 % were amphetamine-related.

Look for Drug law offences in the Statistical bulletin for additional data.  

National drug laws

The Narcotic Substances and Precursors Control Act (NSPCA) was approved on 2 April 1999. Further amendments passed in 2010 harmonised the NSPCA with other national legal Acts, and clarified drug coordination mechanisms at the national and regional levels, the roles of different entities involved in drug-related activities, and the establishment of the national focal point, and added several new controlled substances and plants.

In 2004 the Penal Code was amended to remove the clause that exonerated drug users found in possession of a drug in a quantity that suggested that it was for personal use. An amendment adopted in 2006 reduced sanctions for drug possession, and also took into account the differentiation between high-risk and moderate-risk substances. Drug use itself is penalised as an administrative offence for high-risk drugs (List 1) and a fine can be imposed of between BGN 2 000–5 000. Minor cases of possession prosecuted under the Penal Code can be settled with a fine of up to BGN 1 000; otherwise, possession of any drug is punished by one to six years’ imprisonment for high-risk substances and up to five years for moderate-risk substances.

Trafficking carries penalties of imprisonment of between two and eight years for high-risk substances and one to six years for moderate-risk substances, but particularly large amounts or other aggravating circumstances can result in prison sentences of up to 15 years.

Go to the European Legal Database on Drugs (ELDD) for additional information.  

National drug strategy

The National Anti-Drug Strategy 2009–13 was adopted on 22 October 2008 by the National Drugs Council at its third regular meeting. The strategy takes into account both the European Union Drugs Strategy 2005–12 and an assessment of the implementation of the Bulgarian National Anti-Drug Strategy 2003–08, ensuring it is balanced and comprehensive. Both the National Anti-Drug Strategy 2009–13 and the Action Plan that supports its implementation are based on the five pillars of: demand reduction; supply reduction; information systems and research; coordination and international cooperation; and legislative improvement. Focusing on illicit drugs, the strategy has two main goals: (i) to protect the health and welfare of both the public and individuals and to guarantee a high level of public security through a balanced and integrated approach to drugs and drug use; and (ii) to reduce the supply of illicit drugs and chemical precursors through the use of efficient law enforcement and control agencies, alongside taking preventative action against drug-related crime and ensuring effective collaboration through a common approach. During 2013 an interdepartmental group was established to develop a new national drugs strategy and action plan for the period 2014–18.


Coordination mechanism in the field of drugs

Established in 2001 by the Narcotic Substances and Precursors Control Act of 1999, the National Drugs Council is a body of the Council of Ministers of the Republic of Bulgaria. Operating at the inter-ministerial level, it is responsible for the implementation and coordination of policy against drug abuse and drug trafficking. Chaired by the Minister of Health, the Council includes three deputy chairpersons (the Secretary General of the Ministry of the Interior, the Deputy Chairperson of the State Agency for National Security and a Deputy Minister of Justice), a secretary and 24 members. Key ministries involved in the fight against drugs are represented on the Council, including the President of the Republic of Bulgaria, the Supreme Court of Cassation, the Supreme Administrative Court, the Supreme Prosecutor’s Office of Cassation, the National Investigation Office and other institutions.

The Narcotic Substances Section is part of the Pharmaceutical Products, Medical Devices and Narcotic Substances Directorate at the Ministry of Health. It is responsible for assisting the Minister to control scheduled substances for medical purposes and meet Bulgaria’s obligations under international drug-control treaties.

By the end of 2011 the Council had established 27 Municipal Councils on Narcotic Substances. These bodies function as regional/local coordination structures in municipalities that are regional administrative centres. The Municipal Councils are complemented by 27 prevention and information centres that operate at the city/local level. The centres collect, analyse and provide information for the coordination and implementation of programmes and strategies at the municipal level.

Public expenditure

In past years the financing of drug-related activities in Bulgaria was decided annually by those entities in charge of their implementation. However, more recently, according to the National Drug Strategy for 2009–2013, the National Programme has been one of the main guides for the planning of public financing for drug-related initiatives. Therefore, estimates for drug-related public expenditure have begun to being reported. However, it is not possible to assess what proportion of the total effectively spent that is represented by estimates.

Authorities estimate that in 2013 a total of BGN 607 978 were allocated at the level of central government for labelled drug-related expenditure, while BGN 64 800 were allocated at the regional level and BGN 180 650 at the level of municipalities.

Drug-related research

Most drug-related research in Bulgaria focuses on the prevalence and characteristics of drug use among the general population and among other categories of the population (including those in school, university and prison settings), and on the health and legal consequences of drug use. Most of the studies have been carried out by or with the active participation of the national focal point.

Other studies mentioned in the latest National reports include research on the prevalence, incidence and patterns of drug use among new clients, responses to the drug situation, the consequences of drug use and drug markets.

See Drug-related research for more detailed information. 

Key national figures and statistics

b Break in time series.

e Estimated.

p Eurostat provisional value.

1 Gross domestic product (GDP) is a measure of economic activity. It is defined as the value of all goods and services produced less the value of any goods or services used in their creation. The volume index of GDP per capita in Purchasing Power Standards (PPS) is expressed in relation to the European Union (EU-27) average set to equal 100. If the index of a country is higher than 100, this country's level of GDP per head is higher than the EU average and vice versa.

2  Expenditure on social protection contains: benefits, which consist of transfers, in cash or in kind to households and individuals to relieve them of the burden of a defined set of risks or needs.

3 Unemployment rates represent unemployed persons as a percentage of the labour force. Unemployed persons comprise persons aged 15 to 74 who were: (a) without work during the reference week; (b) currently available for work; (c) actively seeking work.

4 Situation of penal institutions on 1 September, 2012.

5 Share of persons aged 0+ with an equivalent disposable income below the at-risk-of-poverty threshold, which is set at 60 % of the national median equivalised disposable income (after social transfers).

  Year  Bulgaria EU (28 countries) Source
Population  2014 7 245 677
506 824 509 ep
Population by age classes 15–24  2014 10.4 % 11.3 % bep
25–49 35.2 % 34.7 % bep
50–64 21.1 % 19.9 % bep
GDP per capita in PPS (Purchasing Power Standards) 1  2013 45 100 Eurostat
Total expenditure on social protection (% of GDP) 2  2012 17.4 % 29.5 % p Eurostat
Unemployment rate 3  2014 11.4 % 10.2 % Eurostat
Unemployment rate of population aged under 25 years  2014 23.8 % 22.2 % Eurostat
Prison population rate (per 100 000 of national population) 4  2013 1121.3  : Council of Europe, SPACE I-2013
At risk of poverty rate 5  2013 21.0 % 16.6 %  SILC

Data sheet — key statistics on the drug situation

        EU range      
  Year   Country data Min. Max. Average Rank Reporting Countries
Problem opioid use (rate/1 000) :   : 0.2 10.7      
All clients entering treatment (%) 2013   93.2% 6% 93%      
New clients entering treatment (%) 2013   79.3% 2% 81%      
Purity — heroin brown (%) 2013   17.3% 6% 42%   11 24
Price per gram — heroin brown (EUR) 2013   EUR 32 EUR 25 EUR 158   3 22
Prevalence of drug use — schools (%) 2011   4.0% 1% 5%      
Prevalence of drug use — young adults (%) 2012   0.3% 0% 4% 2%    
Prevalence of drug use — all adults (%) 2012   0.2% 0% 2% 1% 3 26
All clients entering treatment (%) 2013   0.0% 0% 39%      
New clients entering treatment (%) 2013   2.6% 0% 40%      
Purity (%) 2013   30.5% 20% 75%   5 27
Price per gram (EUR) 2013   EUR 56 EUR 47 EUR 103   7 24
Prevalence of drug use — schools (%) 2011   7.0% 1% 7%      
Prevalence of drug use — young adults (%) 2012   1.3% 0% 3% 1%    
Prevalence of drug use — all adults (%) 2012   0.6% 0% 1% 1% 15 25
All clients entering treatment (%) 2013   5.0% 0% 70%      
New clients entering treatment (%) 2013   10.9% 0% 74%      
Purity (%) 2013   8.5% 5% 71%   5 25
Price per gram (EUR) 2013   EUR 10 EUR 8 EUR 63   8 21
Prevalence of drug use — schools (%) 2011   4.0% 1% 4%      
Prevalence of drug use — young adults (%) 2012   2.9% 0% 3% 1%    
Prevalence of drug use — all adults (%) 2012   1.2% 0% 2% 1% 22 25
All clients entering treatment (%) 2013   0.1% 0% 2%      
New clients entering treatment (%) 2013   0.0% 0% 4%      
Purity (mg of MDMA base per unit) :   : 26 mg 144 mg      
Price per tablet (EUR) 2013   EUR 7 EUR 3 EUR 24   8 19
Prevalence of drug use — schools (%) 2011   24.0% 5% 42%      
Prevalence of drug use — young adults (%) 2012   8.3% 0% 22% 12%    
Prevalence of drug use — all adults (%) 2012   3.5% 0% 9% 6% 8 27
All clients entering treatment (%) 2013   4.1% 3% 63%      
New clients entering treatment (%) 2013   4.5% 5% 80%      
Potency — herbal (%) 2013   9.1% 2% 13%   11 22
Potency — resin (%) 2013   9.6% 3% 22%   6 20
Price per gram — herbal (EUR) 2013   EUR 7 EUR 4 EUR 25   5 19
Price per gram — resin (EUR) 2013   EUR 14 EUR 3 EUR 21   18 21
Prevalence of problem drug use                
Problem drug use (rate/1 000) 2009   6.01 2.0 10.0      
Injecting drug use (rate/1 000) :   : 0.2 9.2      
Drug-related infectious diseases/deaths                
HIV infections newly diagnosed (rate/million) 2013   4.5 0.0 54.5      
HIV prevalence (%) :   : 0% 49%      
HCV prevalence (%) :   : 14% 84%      
Drug-related deaths (rate/million) 2013   2.9 1.5 84.1      
Health and social responses                
Syringes distributed 2013   431 568 124 406 9 239 506      
Clients in substitution treatment 2013   3 563 180 172 513      
Treatment demand                
All clients 2013   1 957 289 101 753      
New clients 2013   489 19 35 229      
All clients with known primary drug 2013   1 871 287 99 186      
New clients with known primary drug 2013   266 19 34 524      
Drug law offences                
Number of reports of offences 2013   9 521 429 426 707      
Offences for use/possession 2013   5 249 58 397 713      



See the explanatory notes for further information on the methods and definitions.

Only the most recent data are available for each key statistic. Data before 2006 were excluded.

Additional sources of national information

In addition to the information provided above, you might find the following resources useful sources of national data.

Page last updated: Wednesday, 03 June 2015